Cypress, the Cypress logo and PSoC are registered trademarks of Cypress Semiconductor Corporation. All other trademarks are property of their owners.
CYPRESS SEMICONDUCTOR CORPORATION |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
September 29, 2019 |
|
December 30, 2018 |
||||
|
|
|
|
|
||||
ASSETS |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
343,027 |
|
|
$ |
285,720 |
|
Accounts receivable, net |
|
389,896 |
|
|
324,274 |
|
||
Inventories |
|
327,392 |
|
|
292,093 |
|
||
Assets held for sale |
|
— |
|
|
13,510 |
|
||
Property, plant and equipment, net |
|
262,955 |
|
|
282,986 |
|
||
Goodwill and other intangible assets, net |
|
1,708,676 |
|
|
1,864,340 |
|
||
Other assets |
|
628,045 |
|
|
630,292 |
|
||
Total assets |
|
$ |
3,659,991 |
|
|
$ |
3,693,215 |
|
LIABILITIES AND EQUITY |
|
|
|
|
||||
Accounts payable |
|
$ |
181,704 |
|
|
$ |
210,715 |
|
Income tax liabilities |
|
55,228 |
|
|
53,469 |
|
||
Revenue reserves, deferred margin and other liabilities |
|
503,801 |
|
|
430,814 |
|
||
Current portion of long-term debt |
|
63,518 |
|
|
6,943 |
|
||
Revolving credit facility and long-term debt |
|
756,853 |
|
|
874,235 |
|
||
Total liabilities |
|
1,561,104 |
|
|
1,576,176 |
|
||
Total Cypress stockholders' equity |
|
2,098,887 |
|
|
2,115,734 |
|
||
Non-controlling interest |
|
— |
|
|
1,305 |
|
||
Total equity |
|
2,098,887 |
|
|
2,117,039 |
|
||
Total liabilities and equity |
|
$ |
3,659,991 |
|
|
$ |
3,693,215 |
|
CYPRESS SEMICONDUCTOR CORPORATION |
|||||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||||||||||
ON A GAAP BASIS |
|||||||||||||||||||
(In thousands, except per-share data) |
|||||||||||||||||||
(Unaudited) |
|||||||||||||||||||
|
|||||||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||
|
September 29,
|
|
June 30,
|
|
September 30,
|
|
September 29,
|
|
September 30,
|
||||||||||
Revenues |
$ |
574,521 |
|
|
$ |
532,221 |
|
|
$ |
673,035 |
|
|
$ |
1,645,746 |
|
|
$ |
1,879,366 |
|
Cost of revenue |
358,080 |
|
|
333,463 |
|
|
413,320 |
|
|
1,028,138 |
|
|
1,173,121 |
|
|||||
Gross profit |
216,441 |
|
|
198,758 |
|
|
259,715 |
|
|
617,608 |
|
|
706,245 |
|
|||||
Research and development |
89,253 |
|
|
93,639 |
|
|
91,691 |
|
|
271,498 |
|
|
281,617 |
|
|||||
Selling, general and administrative |
81,963 |
|
|
91,633 |
|
|
92,943 |
|
|
255,583 |
|
|
262,940 |
|
|||||
Total operating expenses |
171,216 |
|
|
185,272 |
|
|
184,634 |
|
|
527,081 |
|
|
544,557 |
|
|||||
Operating income |
45,225 |
|
|
13,486 |
|
|
75,081 |
|
|
90,527 |
|
|
161,688 |
|
|||||
Interest and other expense, net |
(14,922 |
) |
|
(12,003 |
) |
|
(15,059 |
) |
|
(36,168 |
) |
|
(47,356 |
) |
|||||
Income before income taxes, share in gain/loss, net and impairment of equity method investees and non-controlling interest |
30,303 |
|
|
1,483 |
|
|
60,022 |
|
|
54,359 |
|
|
114,332 |
|
|||||
Income tax (provision) benefit |
(16,247 |
) |
|
18,189 |
|
|
(5,618 |
) |
|
2,672 |
|
|
(15,829 |
) |
|||||
Share in gain/loss, net and impairment of equity method investees |
(1,383 |
) |
|
(32,405 |
) |
|
(3,657 |
) |
|
(37,378 |
) |
|
(10,873 |
) |
|||||
Net income (loss) |
12,673 |
|
|
(12,733 |
) |
|
50,747 |
|
|
19,653 |
|
|
87,630 |
|
|||||
Net loss (income) attributable to non-controlling interest |
10 |
|
|
4 |
|
|
(52 |
) |
|
15 |
|
|
(152 |
) |
|||||
Net income (loss) attributable to Cypress |
$ |
12,683 |
|
|
$ |
(12,729 |
) |
|
$ |
50,695 |
|
|
$ |
19,668 |
|
|
$ |
87,478 |
|
Net income (loss) per share attributable to Cypress: |
|
|
|
|
|
|
|
|
|
||||||||||
Basic |
$ |
0.03 |
|
|
$ |
(0.03 |
) |
|
$ |
0.14 |
|
|
$ |
0.05 |
|
|
$ |
0.24 |
|
Diluted |
$ |
0.03 |
|
|
$ |
(0.03 |
) |
|
$ |
0.14 |
|
|
$ |
0.05 |
|
|
$ |
0.23 |
|
Cash dividend declared per share |
$ |
0.11 |
|
|
$ |
0.11 |
|
|
$ |
0.11 |
|
|
$ |
0.33 |
|
|
$ |
0.33 |
|
Shares used in net income (loss) per share calculation: |
|
|
|
|
|
|
|
|
|
||||||||||
Basic |
369,241 |
|
|
365,600 |
|
|
361,631 |
|
|
366,444 |
|
|
358,560 |
|
|||||
Diluted |
388,243 |
|
|
365,600 |
|
|
374,266 |
|
|
381,633 |
|
|
373,064 |
|
CYPRESS SEMICONDUCTOR CORPORATION |
||||||||||||||||
RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES |
||||||||||||||||
(In thousands, except percentages and per-share data) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
Table A: GAAP to non-GAAP reconciling items: Three Months Ended Q3 2019 |
|
|
||||||||||||||
|
|
Cost of revenues |
|
Research and
|
|
Selling, general
|
|
Interest and other
|
||||||||
GAAP [i] |
|
$ |
358,080 |
|
|
$ |
89,253 |
|
|
$ |
81,963 |
|
|
$ |
(16,305 |
) |
[1] Stock-based compensation |
|
5,907 |
|
|
7,708 |
|
|
11,276 |
|
|
— |
|
||||
[2] Changes in value of deferred compensation plan |
|
(6 |
) |
|
(38 |
) |
|
(37 |
) |
|
237 |
|
||||
[3] Gain on sale of NAND business to joint venture |
|
— |
|
|
— |
|
|
— |
|
|
(1,887 |
) |
||||
[4] Share in gain/loss, net of equity method investees |
|
— |
|
|
— |
|
|
— |
|
|
1,383 |
|
||||
[5] Imputed interest on convertible debt, equity component amortization on convertible debt and others |
|
— |
|
|
— |
|
|
— |
|
|
3,101 |
|
||||
[6] Amortization of debt issuance costs |
|
— |
|
|
— |
|
|
— |
|
|
626 |
|
||||
[7] Loss on extinguishment of debt |
|
— |
|
|
— |
|
|
— |
|
|
6,402 |
|
||||
[8] Amortization of acquisition-related intangible assets and other |
|
47,084 |
|
|
— |
|
|
4,310 |
|
|
— |
|
||||
[9] Restructuring charges |
|
(68 |
) |
|
291 |
|
|
169 |
|
|
— |
|
||||
[10] Merger-related expenses |
|
— |
|
|
— |
|
|
3,043 |
|
|
— |
|
||||
[11] Other income and expenses |
|
— |
|
|
280 |
|
|
381 |
|
|
(631 |
) |
||||
Non - GAAP [ii] |
|
$ |
305,163 |
|
|
$ |
81,012 |
|
|
$ |
62,821 |
|
|
$ |
(7,074 |
) |
Impact of reconciling items [ii - i] |
|
$ |
(52,917 |
) |
|
$ |
(8,241 |
) |
|
$ |
(19,142 |
) |
|
$ |
9,231 |
|
Table B: GAAP to non-GAAP reconciling items: Three Months Ended Q2 2019 |
|
|
||||||||||||||
|
|
Cost of revenues |
|
Research and
|
|
Selling, general
|
|
Interest and other
|
||||||||
GAAP [i] |
|
$ |
333,463 |
|
|
$ |
93,639 |
|
|
$ |
91,633 |
|
|
$ |
(44,408 |
) |
[1] Stock-based compensation |
|
2,817 |
|
|
12,304 |
|
|
15,359 |
|
|
— |
|
||||
[2] Changes in value of deferred compensation plan |
|
130 |
|
|
632 |
|
|
627 |
|
|
(1,145 |
) |
||||
[3] Share in gain/loss, net and impairment of equity method investees 1 |
|
— |
|
|
— |
|
|
— |
|
|
32,405 |
|
||||
[4] Imputed interest on convertible debt, equity component amortization on convertible debt and others |
|
— |
|
|
— |
|
|
— |
|
|
3,276 |
|
||||
[5] Amortization of debt issuance costs |
|
— |
|
|
— |
|
|
— |
|
|
929 |
|
||||
[6] Amortization of acquisition-related intangible assets and other |
|
47,293 |
|
|
— |
|
|
4,304 |
|
|
— |
|
||||
[7] Restructuring charges |
|
1,018 |
|
|
1,362 |
|
|
641 |
|
|
— |
|
||||
[8] Merger-related expenses |
|
— |
|
|
— |
|
|
8,409 |
|
|
— |
|
||||
[9] Other income and expenses |
|
— |
|
|
— |
|
|
32 |
|
|
(103 |
) |
||||
Non - GAAP [ii] |
|
$ |
282,205 |
|
|
$ |
79,341 |
|
|
$ |
62,261 |
|
|
$ |
(9,046 |
) |
Impact of reconciling items [ii - i] |
|
$ |
(51,258 |
) |
|
$ |
(14,298 |
) |
|
$ |
(29,372 |
) |
|
$ |
35,362 |
|